HRMY Harmony Biosciences Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1802665 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.8%
TTM net income YoY-3.8%
TTM EPS YoY-4.7%
Revenue 3-yr CAGR22.2%
Net income 3-yr CAGR5.8%
Margins
Gross margin74.0%
Operating margin22.2%
Net margin18.1%
FCF margin—
EBITDA margin—
Returns
ROE18.7%
ROA13.3%
ROIC (approx.)36.1%
Asset turnover0.74x
Leverage & solvency
Liabilities / assets27.5%
Debt / equity0.14x
Current ratio3.44x
Interest coverage16.99x
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $868.45M | $714.73M |
| Cost of revenue | $198.34M | $156.81M |
| Gross profit | $670.11M | $557.92M |
| R&D expense | $189.59M | $145.82M |
| SG&A expense | $152.54M | $110.35M |
| Operating income | $208.47M | $190.83M |
| Interest expense | $14.65M | $17.50M |
| Pretax income | $215.06M | $191.80M |
| Income tax | $56.38M | $46.31M |
| Net income | $158.69M | $145.49M |
| EBITDA | — | $191.09M |
| EPS (basic) | 2.76 | 2.56 |
| EPS (diluted) | 2.71 | 2.51 |
| Weighted avg. shares (diluted) | 58.54M | 57.87M |
| Balance sheet | ||
| Cash & equivalents | $752.50M | $453.27M |
| Short-term investments | $22.84M | $14.19M |
| Receivables | $96.79M | $83.03M |
| Inventory | $5.36M | $7.20M |
| Current assets | $907.01M | $579.25M |
| PP&E, net | — | $1.26M |
| Intangibles | $89.42M | $113.26M |
| Total assets | $1.27B | $999.20M |
| Current liabilities | $252.13M | $175.08M |
| Short-term debt | $20.00M | $16.25M |
| Long-term debt | $143.66M | $163.02M |
| Total debt | $163.66M | $179.27M |
| Total liabilities | $401.41M | $340.05M |
| Shareholders' equity | $870.22M | $659.15M |
| Net debt | -$588.84M | -$274.00M |
| Shares outstanding | 57.73M | 57.14M |
| Cash flow statement | ||
| Operating cash flow | $348.20M | $219.82M |
| Capital expenditure | $310,000 | $1.15M |
| Free cash flow | $347.89M | $218.67M |
| Investing cash flow | -$39.65M | -$67.48M |
| Financing cash flow | -$9.05M | -$11.00M |
| Depreciation & amortization | — | $267,000 |
| Stock-based compensation | $44.90M | $42.60M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.